MSTX The third quarter was productive for Mast. Consistent with prior guidance, our 388-patient pivotal Phase 3 study of MST-188 for sickle cell disease is on track to complete enrollment by the end of next year. We now have opened 50 study sites in the U.S. and more than ten study sites in six countries outside of the U.S."
Upcoming News and Events
•
Phase 2 Study (heart failure): submit protocol to FDA
Q4 2014
•
Nonclinical Study (heart failure): data
Q1 2015
•
Nonclinical Study (embolic stroke): data
Q2 2015
•
Phase 2 Study (heart failure): initiate enrollment
1H 2015
•
EPIC Extension Study (repeat exposure): initiate enrollment
1H 2015
•
Phase 2a Study of AIR001 (WHO Group 2 PH): preliminary data
2H 2015
•
Phase 2 Study (heart failure): interim safety analysis
2H 2015
•
EPIC Study: complete enrollment
Q4 2015
•
EPIC Study: top-line data
Q1 2016
•
Phase 2 Study (acute limb ischemia): complete enrollment
Balance Sheet Highlights
As of September 30, 2014, the Company had cash, cash equivalents and investment securities totaling $43.1 million. Stockholders' equity amounted to $45.2 million as of September 30, 2014.
